Suboptimal response in CML linked to Gleevec uptake in cells
Australian researchers have confirmed the protein involved in Gleevec’s transport into chronic myelogenousleukemia (CML) cells and have shown that it is the activity of this protein which is a key determinant of response in CML patients.